At KSQ Therapeutics, we seek to understand the role of every human gene in each disease, each tissue, and each cell that we study. This comprehensive approach has resulted in a massive, experimentally derived dataset that we have found to be remarkably predictive of past successes and failures in oncology and immuno-oncology product development. Utilizing this approach, we also identified a number of opportunities for the development of new medicines. As a result, we have aggressively invested in these distinct, highly validated pathways for new drug development with the expectation that the medicines we create may become the next breakthrough products for patients.
Founded in late 2015, KSQ is a clinical-stage biotech that has rapidly advanced the field of CRISPR-enabled functional genomics, from in vitro cell autonomous screens to more complex genome-scale screens of immune cells in vivo. The company has expanded the scope of its technology to include multiple cell types and to unlock areas beyond oncology. KSQ is led by a team of accomplished industry experts in drug discovery and development.
KSQ Therapeutics is seeking a Senior Associate Scientist/Scientist with an interest in discovering and advancing NK cell therapies for the treatment of cancer to join our team. Our ideal candidate thrives in a research environment that demands teamwork, scientific rigor and technical excellence. Hands-on in vivo model development required. Interested people with experience in the discovery and development of NK/adoptive cell therapies strongly encouraged to apply. Ideal candidate would be able to independently execute in vivo and ex vivo activities to support the progression of our NK cell focused partnership with Takeda. Working as part of a team to ensure delivery of key data sets as well as develop and deliver scientific presentations and reports in an efficient manner also required.
Minimum experience required: